Loading…

Highly antibiotic‐resistant Clostridium difficile isolates from Iranian patients

Aims Little is known about the resistance rate and susceptibility profile of Clostridium difficile isolates in Iran. Therefore, the aim of present study is to assess the rate of drug‐resistant C. difficile. Methods and Results During a 6‐year period, four hospitals submitted 735 stool specimens from...

Full description

Saved in:
Bibliographic Details
Published in:Journal of applied microbiology 2018-11, Vol.125 (5), p.1518-1525
Main Authors: Baghani, A., Ghourchian, S., Aliramezani, A., Yaseri, M., Mesdaghinia, A., Douraghi, M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3535-e6e0485341789e4ca92a0d231bf960a42aa52c764f28fa739c07cf5d233d5c233
cites cdi_FETCH-LOGICAL-c3535-e6e0485341789e4ca92a0d231bf960a42aa52c764f28fa739c07cf5d233d5c233
container_end_page 1525
container_issue 5
container_start_page 1518
container_title Journal of applied microbiology
container_volume 125
creator Baghani, A.
Ghourchian, S.
Aliramezani, A.
Yaseri, M.
Mesdaghinia, A.
Douraghi, M.
description Aims Little is known about the resistance rate and susceptibility profile of Clostridium difficile isolates in Iran. Therefore, the aim of present study is to assess the rate of drug‐resistant C. difficile. Methods and Results During a 6‐year period, four hospitals submitted 735 stool specimens from patients suspected for C. difficile infections to the anaerobic bacteriology laboratory. The 46 C. difficile isolates were subjected to disc diffusion and minimum inhibitory concentration (MIC) Test Strips. All isolates were susceptible to vancomycin (VAN) while the highly resistant phenotypes of metronidazole (MTZ) (67·4%), moxifloxacin (78·3%), ciprofloxacin (69·5%) and tetracycline (82·6%) were observed. Of more concern, 67·3% of C. difficile isolates displayed multidrug‐resistant phenotypes. More than half of the isolates (n = 27, 58·6%) were coresistant to ciprofloxacin and moxifloxacin. The MIC90 of VAN was ≤2 mg l−1, whereas this value for MTZ, ciprofloxacin, moxifloxacin and tetracycline was higher than the resistance breakpoints. According to the comparison of interpretive categories for two tests, the categorical agreement was less than 90% for VAN, ciprofloxacin and tetracycline. Conclusions The disc diffusion method can be used to detect the isolates with reduced susceptibility to MTZ or moxifloxacin. The high rate of resistance to fluoroquinolones highlights the possibility of the emergence of hypervirulent strains in our settings. Significance and Impact of the Study This study provides data regarding the high level of resistance against multiple antibiotics except VAN.
doi_str_mv 10.1111/jam.14035
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2062834056</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2120019052</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3535-e6e0485341789e4ca92a0d231bf960a42aa52c764f28fa739c07cf5d233d5c233</originalsourceid><addsrcrecordid>eNp1kM1KAzEURoMotlYXvoAMuNHFtPmd6SxLUVupCKLrkGYSTZmZ1CSDdOcj-Iw-ibFTXQhmkVwuh48vB4BTBIcontFK1ENEIWF7oI9IxlKc5Xh_O9OUwRz3wJH3KwgRgSw7BD1cFCwfF6QPHmbm-aXaJKIJZmlsMPLz_cMpb3yIq2RaWR-cKU1bJ6XR2khTqcR4W4mgfKKdrZO5E40RTbIWwagm-GNwoEXl1cnuHYCn66vH6Sxd3N_Mp5NFKgkjLFWZgnTMCEWxiaJSFFjAEhO01EUGBcVCMCzzjGo81iInhYS51CwSpGQy3gNw0eWunX1tlQ-8Nl6qqhKNsq3nGGZ4TGj8cUTP_6Ar27omtuMY4eilgAxH6rKjpLPeO6X52plauA1HkH-L5lE034qO7NkusV3Wqvwlf8xGYNQBb9HY5v8kfju56yK_AAihh6k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2120019052</pqid></control><display><type>article</type><title>Highly antibiotic‐resistant Clostridium difficile isolates from Iranian patients</title><source>Alma/SFX Local Collection</source><creator>Baghani, A. ; Ghourchian, S. ; Aliramezani, A. ; Yaseri, M. ; Mesdaghinia, A. ; Douraghi, M.</creator><creatorcontrib>Baghani, A. ; Ghourchian, S. ; Aliramezani, A. ; Yaseri, M. ; Mesdaghinia, A. ; Douraghi, M.</creatorcontrib><description>Aims Little is known about the resistance rate and susceptibility profile of Clostridium difficile isolates in Iran. Therefore, the aim of present study is to assess the rate of drug‐resistant C. difficile. Methods and Results During a 6‐year period, four hospitals submitted 735 stool specimens from patients suspected for C. difficile infections to the anaerobic bacteriology laboratory. The 46 C. difficile isolates were subjected to disc diffusion and minimum inhibitory concentration (MIC) Test Strips. All isolates were susceptible to vancomycin (VAN) while the highly resistant phenotypes of metronidazole (MTZ) (67·4%), moxifloxacin (78·3%), ciprofloxacin (69·5%) and tetracycline (82·6%) were observed. Of more concern, 67·3% of C. difficile isolates displayed multidrug‐resistant phenotypes. More than half of the isolates (n = 27, 58·6%) were coresistant to ciprofloxacin and moxifloxacin. The MIC90 of VAN was ≤2 mg l−1, whereas this value for MTZ, ciprofloxacin, moxifloxacin and tetracycline was higher than the resistance breakpoints. According to the comparison of interpretive categories for two tests, the categorical agreement was less than 90% for VAN, ciprofloxacin and tetracycline. Conclusions The disc diffusion method can be used to detect the isolates with reduced susceptibility to MTZ or moxifloxacin. The high rate of resistance to fluoroquinolones highlights the possibility of the emergence of hypervirulent strains in our settings. Significance and Impact of the Study This study provides data regarding the high level of resistance against multiple antibiotics except VAN.</description><identifier>ISSN: 1364-5072</identifier><identifier>EISSN: 1365-2672</identifier><identifier>DOI: 10.1111/jam.14035</identifier><identifier>PMID: 29957893</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Anti-Infective Agents - pharmacology ; Antibiotic resistance ; antibiotic susceptibility testing ; Antibiotics ; Bacteria ; Bacteriology ; Breakpoints ; Ciprofloxacin ; Ciprofloxacin - pharmacology ; Clostridium difficile ; Clostridium difficile - drug effects ; Clostridium difficile - isolation &amp; purification ; Clostridium difficile - pathogenicity ; Clostridium Infections - drug therapy ; Clostridium Infections - microbiology ; disc diffusion ; Drug Resistance, Multiple, Bacterial ; Fluoroquinolones ; Fluoroquinolones - pharmacology ; Humans ; Iran ; Metronidazole ; Metronidazole - pharmacology ; MIC Test Strips ; Microbial Sensitivity Tests ; Minimum inhibitory concentration ; Moxifloxacin ; Patients ; Phenotypes ; resistance ; Vancomycin ; Vancomycin - pharmacology</subject><ispartof>Journal of applied microbiology, 2018-11, Vol.125 (5), p.1518-1525</ispartof><rights>2018 The Society for Applied Microbiology</rights><rights>2018 The Society for Applied Microbiology.</rights><rights>Copyright © 2018 The Society for Applied Microbiology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3535-e6e0485341789e4ca92a0d231bf960a42aa52c764f28fa739c07cf5d233d5c233</citedby><cites>FETCH-LOGICAL-c3535-e6e0485341789e4ca92a0d231bf960a42aa52c764f28fa739c07cf5d233d5c233</cites><orcidid>0000-0001-5861-3182</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29957893$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baghani, A.</creatorcontrib><creatorcontrib>Ghourchian, S.</creatorcontrib><creatorcontrib>Aliramezani, A.</creatorcontrib><creatorcontrib>Yaseri, M.</creatorcontrib><creatorcontrib>Mesdaghinia, A.</creatorcontrib><creatorcontrib>Douraghi, M.</creatorcontrib><title>Highly antibiotic‐resistant Clostridium difficile isolates from Iranian patients</title><title>Journal of applied microbiology</title><addtitle>J Appl Microbiol</addtitle><description>Aims Little is known about the resistance rate and susceptibility profile of Clostridium difficile isolates in Iran. Therefore, the aim of present study is to assess the rate of drug‐resistant C. difficile. Methods and Results During a 6‐year period, four hospitals submitted 735 stool specimens from patients suspected for C. difficile infections to the anaerobic bacteriology laboratory. The 46 C. difficile isolates were subjected to disc diffusion and minimum inhibitory concentration (MIC) Test Strips. All isolates were susceptible to vancomycin (VAN) while the highly resistant phenotypes of metronidazole (MTZ) (67·4%), moxifloxacin (78·3%), ciprofloxacin (69·5%) and tetracycline (82·6%) were observed. Of more concern, 67·3% of C. difficile isolates displayed multidrug‐resistant phenotypes. More than half of the isolates (n = 27, 58·6%) were coresistant to ciprofloxacin and moxifloxacin. The MIC90 of VAN was ≤2 mg l−1, whereas this value for MTZ, ciprofloxacin, moxifloxacin and tetracycline was higher than the resistance breakpoints. According to the comparison of interpretive categories for two tests, the categorical agreement was less than 90% for VAN, ciprofloxacin and tetracycline. Conclusions The disc diffusion method can be used to detect the isolates with reduced susceptibility to MTZ or moxifloxacin. The high rate of resistance to fluoroquinolones highlights the possibility of the emergence of hypervirulent strains in our settings. Significance and Impact of the Study This study provides data regarding the high level of resistance against multiple antibiotics except VAN.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Anti-Infective Agents - pharmacology</subject><subject>Antibiotic resistance</subject><subject>antibiotic susceptibility testing</subject><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Bacteriology</subject><subject>Breakpoints</subject><subject>Ciprofloxacin</subject><subject>Ciprofloxacin - pharmacology</subject><subject>Clostridium difficile</subject><subject>Clostridium difficile - drug effects</subject><subject>Clostridium difficile - isolation &amp; purification</subject><subject>Clostridium difficile - pathogenicity</subject><subject>Clostridium Infections - drug therapy</subject><subject>Clostridium Infections - microbiology</subject><subject>disc diffusion</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Fluoroquinolones</subject><subject>Fluoroquinolones - pharmacology</subject><subject>Humans</subject><subject>Iran</subject><subject>Metronidazole</subject><subject>Metronidazole - pharmacology</subject><subject>MIC Test Strips</subject><subject>Microbial Sensitivity Tests</subject><subject>Minimum inhibitory concentration</subject><subject>Moxifloxacin</subject><subject>Patients</subject><subject>Phenotypes</subject><subject>resistance</subject><subject>Vancomycin</subject><subject>Vancomycin - pharmacology</subject><issn>1364-5072</issn><issn>1365-2672</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kM1KAzEURoMotlYXvoAMuNHFtPmd6SxLUVupCKLrkGYSTZmZ1CSDdOcj-Iw-ibFTXQhmkVwuh48vB4BTBIcontFK1ENEIWF7oI9IxlKc5Xh_O9OUwRz3wJH3KwgRgSw7BD1cFCwfF6QPHmbm-aXaJKIJZmlsMPLz_cMpb3yIq2RaWR-cKU1bJ6XR2khTqcR4W4mgfKKdrZO5E40RTbIWwagm-GNwoEXl1cnuHYCn66vH6Sxd3N_Mp5NFKgkjLFWZgnTMCEWxiaJSFFjAEhO01EUGBcVCMCzzjGo81iInhYS51CwSpGQy3gNw0eWunX1tlQ-8Nl6qqhKNsq3nGGZ4TGj8cUTP_6Ar27omtuMY4eilgAxH6rKjpLPeO6X52plauA1HkH-L5lE034qO7NkusV3Wqvwlf8xGYNQBb9HY5v8kfju56yK_AAihh6k</recordid><startdate>201811</startdate><enddate>201811</enddate><creator>Baghani, A.</creator><creator>Ghourchian, S.</creator><creator>Aliramezani, A.</creator><creator>Yaseri, M.</creator><creator>Mesdaghinia, A.</creator><creator>Douraghi, M.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TM</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5861-3182</orcidid></search><sort><creationdate>201811</creationdate><title>Highly antibiotic‐resistant Clostridium difficile isolates from Iranian patients</title><author>Baghani, A. ; Ghourchian, S. ; Aliramezani, A. ; Yaseri, M. ; Mesdaghinia, A. ; Douraghi, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3535-e6e0485341789e4ca92a0d231bf960a42aa52c764f28fa739c07cf5d233d5c233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Anti-Infective Agents - pharmacology</topic><topic>Antibiotic resistance</topic><topic>antibiotic susceptibility testing</topic><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Bacteriology</topic><topic>Breakpoints</topic><topic>Ciprofloxacin</topic><topic>Ciprofloxacin - pharmacology</topic><topic>Clostridium difficile</topic><topic>Clostridium difficile - drug effects</topic><topic>Clostridium difficile - isolation &amp; purification</topic><topic>Clostridium difficile - pathogenicity</topic><topic>Clostridium Infections - drug therapy</topic><topic>Clostridium Infections - microbiology</topic><topic>disc diffusion</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Fluoroquinolones</topic><topic>Fluoroquinolones - pharmacology</topic><topic>Humans</topic><topic>Iran</topic><topic>Metronidazole</topic><topic>Metronidazole - pharmacology</topic><topic>MIC Test Strips</topic><topic>Microbial Sensitivity Tests</topic><topic>Minimum inhibitory concentration</topic><topic>Moxifloxacin</topic><topic>Patients</topic><topic>Phenotypes</topic><topic>resistance</topic><topic>Vancomycin</topic><topic>Vancomycin - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baghani, A.</creatorcontrib><creatorcontrib>Ghourchian, S.</creatorcontrib><creatorcontrib>Aliramezani, A.</creatorcontrib><creatorcontrib>Yaseri, M.</creatorcontrib><creatorcontrib>Mesdaghinia, A.</creatorcontrib><creatorcontrib>Douraghi, M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of applied microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baghani, A.</au><au>Ghourchian, S.</au><au>Aliramezani, A.</au><au>Yaseri, M.</au><au>Mesdaghinia, A.</au><au>Douraghi, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Highly antibiotic‐resistant Clostridium difficile isolates from Iranian patients</atitle><jtitle>Journal of applied microbiology</jtitle><addtitle>J Appl Microbiol</addtitle><date>2018-11</date><risdate>2018</risdate><volume>125</volume><issue>5</issue><spage>1518</spage><epage>1525</epage><pages>1518-1525</pages><issn>1364-5072</issn><eissn>1365-2672</eissn><abstract>Aims Little is known about the resistance rate and susceptibility profile of Clostridium difficile isolates in Iran. Therefore, the aim of present study is to assess the rate of drug‐resistant C. difficile. Methods and Results During a 6‐year period, four hospitals submitted 735 stool specimens from patients suspected for C. difficile infections to the anaerobic bacteriology laboratory. The 46 C. difficile isolates were subjected to disc diffusion and minimum inhibitory concentration (MIC) Test Strips. All isolates were susceptible to vancomycin (VAN) while the highly resistant phenotypes of metronidazole (MTZ) (67·4%), moxifloxacin (78·3%), ciprofloxacin (69·5%) and tetracycline (82·6%) were observed. Of more concern, 67·3% of C. difficile isolates displayed multidrug‐resistant phenotypes. More than half of the isolates (n = 27, 58·6%) were coresistant to ciprofloxacin and moxifloxacin. The MIC90 of VAN was ≤2 mg l−1, whereas this value for MTZ, ciprofloxacin, moxifloxacin and tetracycline was higher than the resistance breakpoints. According to the comparison of interpretive categories for two tests, the categorical agreement was less than 90% for VAN, ciprofloxacin and tetracycline. Conclusions The disc diffusion method can be used to detect the isolates with reduced susceptibility to MTZ or moxifloxacin. The high rate of resistance to fluoroquinolones highlights the possibility of the emergence of hypervirulent strains in our settings. Significance and Impact of the Study This study provides data regarding the high level of resistance against multiple antibiotics except VAN.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>29957893</pmid><doi>10.1111/jam.14035</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-5861-3182</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1364-5072
ispartof Journal of applied microbiology, 2018-11, Vol.125 (5), p.1518-1525
issn 1364-5072
1365-2672
language eng
recordid cdi_proquest_miscellaneous_2062834056
source Alma/SFX Local Collection
subjects Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Anti-Infective Agents - pharmacology
Antibiotic resistance
antibiotic susceptibility testing
Antibiotics
Bacteria
Bacteriology
Breakpoints
Ciprofloxacin
Ciprofloxacin - pharmacology
Clostridium difficile
Clostridium difficile - drug effects
Clostridium difficile - isolation & purification
Clostridium difficile - pathogenicity
Clostridium Infections - drug therapy
Clostridium Infections - microbiology
disc diffusion
Drug Resistance, Multiple, Bacterial
Fluoroquinolones
Fluoroquinolones - pharmacology
Humans
Iran
Metronidazole
Metronidazole - pharmacology
MIC Test Strips
Microbial Sensitivity Tests
Minimum inhibitory concentration
Moxifloxacin
Patients
Phenotypes
resistance
Vancomycin
Vancomycin - pharmacology
title Highly antibiotic‐resistant Clostridium difficile isolates from Iranian patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T18%3A22%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Highly%20antibiotic%E2%80%90resistant%20Clostridium%20difficile%20isolates%20from%20Iranian%20patients&rft.jtitle=Journal%20of%20applied%20microbiology&rft.au=Baghani,%20A.&rft.date=2018-11&rft.volume=125&rft.issue=5&rft.spage=1518&rft.epage=1525&rft.pages=1518-1525&rft.issn=1364-5072&rft.eissn=1365-2672&rft_id=info:doi/10.1111/jam.14035&rft_dat=%3Cproquest_cross%3E2120019052%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3535-e6e0485341789e4ca92a0d231bf960a42aa52c764f28fa739c07cf5d233d5c233%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2120019052&rft_id=info:pmid/29957893&rfr_iscdi=true